Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
End stage kidney disease
What is your approach to managing ESKD patients who are disruptive and threatening in the dialysis unit?
Related Questions
What medications do you use to treat encapsulating peritoneal sclerosis?
Would you make any dialysis prescription modifications for an ESKD patient who develops tachycardia during a hemodialysis session?
How would you approach managing a patient with ESKD on peritoneal dialysis who has a milky appearance of peritoneal effluent but low peritoneal fluid triglyceride levels?
Would you refer an ESKD patient with an identified living donor for AV access placement if kidney transplantation is anticipated in 4 months?
Do you routinely continue dual antibiotic coverage or de-escalate to monotherapy based on peritoneal fluid culture sensitivities in patients with relapsing pseudomonas aeruginosa peritoneal dialysis peritonitis after peritoneal catheter removal?
How should PPIs or H2 blockers be managed in peritoneal dialysis patients with a history of peritonitis and peptic ulcer disease, considering the potential infection risk?
Which ESKD patients would you consider transitioning from hemodialysis to hemodiafiltration, given the FDA approval of a hemodiafiltration system in the US?
How do you approach recommending an AVF for a patient with advanced CKD who is concerned about the cosmetic appearance of the fistula?
Would you use argatroban or citrate catheter lock in a patient with ESKD and HITT?
How do you determine when it is appropriate to transition a patient back to peritoneal dialysis after they were switched to hemodialysis due to PD catheter removal for refractory peritonitis, once the infection has been treated?
